A pharmaceutical company recently completed a 12-week clinical trail of a new painkiller, in which nearly all patients completed the full dosing schedule without interruption.
A researcher analyzing the results concluded that the drug had provided little meaningful relief to patients, pointing to data showing that the average reduction in pain scores across the full course of the trial was only modest.
Goal : Undermine the researcher's conclusion
Pre-thinking: Average reduction in pain scores across full course of the trial does not mean little meaningful relief to patients.
(A) Among patients who entered the trial with the highest initial pain scores, average reductions by the end of the study were greater than those observed in patients who began with only mild or moderate pain. Then new painkiller is more effective on one group of patients than another group of patients.
Incorrect
(B) Patients who adhered to the prescribed dosing schedule without interruption reported substantially greater pain reductions than those who missed at least one dose during the trial.
The patients who missed doses is still a small insignificant group since it is already mentioned that nearly all patients completed full dosing schedule without interruptions.
Incorrect
(C) Patients who were given a placebo rather than the drug reported similarly modest reductions in pain scores over the same 12-week period. This means that the new painkiller is as effective as a placebo. This strengthens the researcher's conclusion that drug has provided little meaningful relief to patients.
Incorrect
(D) Pain score reductions among patients in the trial were negligible during the first eight weeks but accelerated sharply in the final four weeks as the drug reached its full therapeutic concentration in the bloodstream. The drug became more effective when it reached its full therapeutic concentration in the bloodstream. It means is not ineffective in reducing pain in patients.
Correct
(E) The chronic pain condition targeted by the drug is one for which all currently available treatments have historically produced only modest average reductions in standardized pain scores. This provides a comparison of effectiveness of new painkiller with available treatments which also give similar less effective results but does not undermine the researcher's conclusion that the new painkiller provides little relief to patients.
Incorrect
IMO D